Jpmorgan Chase & CO Argenx Se Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARGX
# of Institutions
382Shares Held
31.6MCall Options Held
303KPut Options Held
429K-
Price T Rowe Associates Inc Baltimore, MD5.6MShares$3.3 Billion0.29% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.07 Billion2.39% of portfolio
-
Janus Henderson Group PLC London, X02.47MShares$1.45 Billion0.58% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.92MShares$1.13 Billion0.52% of portfolio
-
Capital World Investors Los Angeles, CA1.51MShares$890 Million0.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $32.6B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...